Skip to content
Revefenacin
Yupelri (revefenacin) is a small molecule pharmaceutical. Revefenacin was first approved as Yupelri on 2018-11-09. It is used to treat chronic obstructive pulmonary disease in the USA. It is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M1, muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M3, and muscarinic acetylcholine receptor M5.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Yupelri
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Revefenacin
Tradename
Company
Number
Date
Products
YUPELRIMylanN-210598 RX2018-11-09
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
yupelriNew Drug Application2019-05-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
chronic obstructive pulmonary diseaseEFO_0000341D029424J44.9
Agency Specific
FDA
EMA
Expiration
Code
REVEFENACIN, YUPELRI, MYLAN IRELAND LTD
2023-11-09NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Revefenacin, Yupelri, Mylan Ireland Ltd
114845312039-10-23U-2440
85414512031-08-25DP
97650282030-07-14DP
105500812030-07-14DP
110082892030-07-14U-2440
72886572025-12-23DP
74917362025-03-10U-2440
75210412025-03-10U-2440
75505952025-03-10DP
75858792025-03-10DS, DPU-2440
79106082025-03-10DS, DP
80349462025-03-10DP
80534482025-03-10U-2440
82738942025-03-10DP
101065032025-03-10U-2440
103439952025-03-10U-2440
112479692025-03-10DP
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03B: Other drugs for obstructive airway diseases, inhalants in atc
— R03BB: Anticholinergics inhalants for obstructive airway diseases
— R03BB08: Revefenacin
HCPCS
Code
Description
J7677
Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Methicillin-resistant staphylococcus aureusD055624—112—4
ImpetigoD007169EFO_1000714L01——2114
EczemaD004485HP_0000964L30.9———112
Atopic dermatitisD003876EFO_0000274L20———2—2
Soft tissue infectionsD018461———1—1
FolliculitisD005499———1—1
CoinfectionD060085———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Orthopedic proceduresD019637—1———1
Bacterial infectionsD001424A49—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameREVEFENACIN
INNrevefenacin
Description
Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.
Classification
Small molecule
Drug classmuscarinic receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1
Identifiers
PDB—
CAS-ID864750-70-9
RxCUI—
ChEMBL IDCHEMBL3833319
ChEBI ID—
PubChem CID11753673
DrugBankDB11855
UNII IDG2AE2VE07O (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CHRM2
CHRM2
CHRM1
CHRM1
CHRM4
CHRM4
CHRM3
CHRM3
CHRM5
CHRM5
Organism
Homo sapiens
Gene name
CHRM2
Gene synonyms
NCBI Gene ID
1129
Protein name
muscarinic acetylcholine receptor M2
Protein synonyms
7TM receptor, acetylcholine receptor, muscarinic 2, muscarinic M2 receptor
Uniprot ID
Q9P1X9
Mouse ortholog
Chrm2 (243764)
muscarinic acetylcholine receptor M2 (Q9ERZ4)
Variants
Clinical Variant
No data
Financial
Yupelri - Theravance Biopharma
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Yupelri - Viatris
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 64 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
711 adverse events reported
View more details